blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1051482

EP1051482 - CYTOTOXIC HETEROMERIC PROTEIN COMBINATORIAL LIBRARIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  29.06.2007
Database last updated on 05.10.2024
Most recent event   Tooltip05.12.2008Lapse of the patent in a contracting state
New state(s): CY		published on 07.01.2009  [2009/02]
Applicant(s)For all designated states
University Health Network
610 University Avenue Toronto
Ontario M5G 2M9 / CA
[2006/34]
Former [2001/14]For all designated states
University Health Network
610 University Avenue
Toronto, Ontario M5G 2M9 / CA
Former [2000/46]For all designated states
The Ontario Cancer Institute
Princess Margaret Hospital, 610 University Avenue
Toronto Ontario MG5 2M9 / CA
Inventor(s)01 / GARIEPY, Jean, Ontario Cancer Inst.
Princess Margaret Hosp., 610 University Avenue
Toronto, Ontario M5G 2M9 / CA
02 / BRAY, Mark, Robert, Ontario Cancer Inst.
Princess Margaret Hosp., 610 University Avenue
Toronto, Ontario M5G 2M9 2M9 / CA
[2000/46]
Representative(s)Barth, Renate
Vossius & Partner
Postfach 86 07 67
81634 München / DE
[N/P]
Former [2000/46]Barth, Renate, Dr.
Vossius & Partner Postfach 86 07 67
81634 München / DE
Application number, filing date98959689.508.12.1998
[2000/46]
WO1998CA01137
Priority number, dateCA1998222299304.02.1998         Original published format: CA 2222993
[2000/46]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9940185
Date:12.08.1999
Language:EN
[1999/32]
Type: A1 Application with search report 
No.:EP1051482
Date:15.11.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 12.08.1999 takes the place of the publication of the European patent application.
[2000/46]
Type: B1 Patent specification 
No.:EP1051482
Date:23.08.2006
Language:EN
[2006/34]
Search report(s)International search report - published on:EP12.08.1999
ClassificationIPC:C12N15/10, C07K14/25, C12Q1/68, A61K31/70, A61K39/02, G01N33/68
[2000/46]
CPC:
C07K14/25 (EP,US); A61P35/00 (EP); C12N15/1055 (EP,US);
A61K38/00 (EP,US)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/46]
TitleGerman:KOMBINATORISCHE BIBLIOTHEKEN HETEROMERER CYTOTOXISCHER PROTEINE[2000/46]
English:CYTOTOXIC HETEROMERIC PROTEIN COMBINATORIAL LIBRARIES[2000/46]
French:BANQUES COMBINATOIRES DE PROTEINES HETEROMERES CYTOTOXIQUES[2000/46]
Entry into regional phase04.09.2000National basic fee paid 
04.09.2000Designation fee(s) paid 
04.09.2000Examination fee paid 
Examination procedure23.08.1999Request for preliminary examination filed
International Preliminary Examining Authority: EP
04.09.2000Examination requested  [2000/46]
08.03.2004Despatch of a communication from the examining division (Time limit: M04)
16.07.2004Reply to a communication from the examining division
25.11.2004Despatch of a communication from the examining division (Time limit: M04)
05.04.2005Reply to a communication from the examining division
07.07.2005Despatch of a communication from the examining division (Time limit: M02)
19.09.2005Reply to a communication from the examining division
25.10.2005Despatch of a communication from the examining division (Time limit: M02)
04.01.2006Reply to a communication from the examining division
20.02.2006Communication of intention to grant the patent
03.07.2006Fee for grant paid
03.07.2006Fee for publishing/printing paid
Opposition(s)24.05.2007No opposition filed within time limit [2007/31]
Fees paidRenewal fee
04.09.2000Renewal fee patent year 03
28.12.2001Renewal fee patent year 04
30.12.2002Renewal fee patent year 05
31.12.2003Renewal fee patent year 06
31.12.2004Renewal fee patent year 07
30.12.2005Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT23.08.2006
BE23.08.2006
CY23.08.2006
FI23.08.2006
IT23.08.2006
NL23.08.2006
DK23.11.2006
SE23.11.2006
GR24.11.2006
ES04.12.2006
IE08.12.2006
LU08.12.2006
MC31.12.2006
PT24.01.2007
[2009/02]
Former [2008/36]AT23.08.2006
BE23.08.2006
FI23.08.2006
IT23.08.2006
NL23.08.2006
DK23.11.2006
SE23.11.2006
GR24.11.2006
ES04.12.2006
IE08.12.2006
LU08.12.2006
MC31.12.2006
PT24.01.2007
Former [2008/21]AT23.08.2006
BE23.08.2006
FI23.08.2006
IT23.08.2006
NL23.08.2006
DK23.11.2006
SE23.11.2006
GR24.11.2006
ES04.12.2006
IE08.12.2006
MC31.12.2006
PT24.01.2007
Former [2008/16]AT23.08.2006
BE23.08.2006
FI23.08.2006
IT23.08.2006
NL23.08.2006
DK23.11.2006
SE23.11.2006
ES04.12.2006
IE08.12.2006
MC31.12.2006
PT24.01.2007
Former [2007/30]AT23.08.2006
BE23.08.2006
FI23.08.2006
NL23.08.2006
DK23.11.2006
SE23.11.2006
ES04.12.2006
PT24.01.2007
Former [2007/23]AT23.08.2006
FI23.08.2006
NL23.08.2006
DK23.11.2006
SE23.11.2006
ES04.12.2006
Former [2007/22]FI23.08.2006
NL23.08.2006
DK23.11.2006
SE23.11.2006
ES04.12.2006
Former [2007/18]FI23.08.2006
NL23.08.2006
SE23.11.2006
ES04.12.2006
Cited inInternational search[XY]  - T. IIDA ET AL., "A single amino acid substitution of Escherichia coli enterotoxin affects its oligomer formation", J. BIOL. CHEM., AM. SOC. BIOCHEM. MOL.BIOL.,INC.,BALTIMORE,US, (19890825), vol. 265, no. 24, pages 14065 - 14070, XP002096323 [X] 1,3,5,8,9,16,17 * see Materials and Methods; page 14068, column R, paragraph 2 * [Y] 1,6
 [DX]  - C. CLARK ET AL., "Phenylalanine 30 plays an important role in receptor binding of verotoxin-1", MOLECULAR MICROBIOL., BLACKWELL, OXFORD, GB, (199602), vol. 19, no. 4, pages 891 - 899, XP002096376 [DX] 1,3,5,8,9,16,17 * the whole document *

DOI:   http://dx.doi.org/10.1046/j.1365-2958.1996.427962.x
 [DXY]  - G.J. TYRELL ET AL., "Alteration of the carbohydrate binding specificity of verotoxins from Gal(alpha)1-4Gal to GalNAc(beta)1-3Gal(alpha)1-4Gal and vice versa by site-directed mutagenesis of the binding subunit", PROC. NATL. ACAD. SCI., NATL. ACAD. SCI.,WASHINGTON,DC,US;, (199201), vol. 89, pages 524 - 528, XP002096324 [DX] 17,18,21 * the whole document * [Y] 1,6

DOI:   http://dx.doi.org/10.1073/pnas.89.2.524
 [DXY]  - L.P. PERERA ET AL., "Identification of three amino acids residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity", J. BACTERIOL., AM. SOC. MICROBIOL.,BALTIMORE,US;, (199102), vol. 173, no. 3, pages 1151 - 1160, XP002096325 [DX] 1-3,5,8-10,16-18,21 * the whole document * [Y] 1,6
 [XY]  - D.J. BAST ET AL., "Toxicity and immunogenecity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits", INFECTION AND IMMUNITY, ASM,WASHINGTON,DC,US, (199706), vol. 65, no. 6, pages 2019 - 2028, XP002096326 [X] 17,18 * the whole document * [Y] 1,6
 [X]  - S.W. LINDGREN ET AL., "The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II related toxin of enterohemorrhagic Escherichia coli differ when measured by vero cell cytotoxicity but not by mouse lethality", INFECTION AND IMMUNITY, ASM,WASHINGTON,DC,US, (199402), vol. 62, no. 2, pages 623 - 631, XP002096327 [X] 1-3,5,8-10,16-18,21 * the whole document *
 [X]  - M.P. JACKSON ET AL., "Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding site subunits by using site-directed mutagenesis", J. BACTERIOL., AM. SOC. MICROBIOL.,BALTIMORE,US;, (199002), vol. 172, no. 2, pages 653 - 658, XP002096328 [X] 1-3,5,8-10,16-18,21 * the whole document *
 [DY]  - J.D. MERMES ET AL., "A reliable method for random mutagenesis: the generation of mutant libraries using spiked oligonucleotide primers", GENE, ELSEVIER SCIENCE PUBLISHERS,B.V.,AMSTERDAM,NL;, (1989), vol. 84, pages 143 - 151, XP002096329 [DY] 1 * the whole document *

DOI:   http://dx.doi.org/10.1016/0378-1119(89)90148-0
 [DY]  - G. DEL RÍO ET AL., "Combinatorial libraries of proteins: Analysis of efficiency of mutagenesis techniques", BIOTECHNIQUES, NATICK, MA, US, (1994), vol. 17, no. 6, pages 1132 - 1139, XP002096330 [DY] 1,6 * the whole document *
 [A]  - A.A. KHINE AND C.A. LINGWOOD, "Capping and receptor-mediated endocytosis of cell-bound verotoxin (Shiga-like toxin) 1: Chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization", J. CELL PHYSIOL., Wiley-Liss, Inc.,new york, US, (199411), vol. 161, no. 2, pages 319 - 332, XP002096331 [A] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1002/jcp.1041610217
 [DA]  - P.-G. NYHOLM ET AL., "Two distinct binding sites for globotriaosyl ceramide on verotoxins: identification by molecular modelling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins", CHEMISTRY AND BIOLOGY, Current Biology LTD, ISSN 1074-5521, (199604), vol. 3, no. 4, pages 263 - 275, XP002096332 [DA] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1074-5521(96)90106-4
 [DA]  - P.G. NYHOLM ET AL., "Modelling of the interaction of verotoxin-1 (VT1) with its glycolipid receptor. globotriaosylceramide (Gb3)", INT. J. BIOL. MACROMOL., Elsevier Science B.V., Amsterdam, NL, (199506), vol. 17, no. 3-4, pages 199 - 204, XP002096333 [DA] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1016/0141-8130(95)92686-K
 [DA]  - P.E. STEIN ET AL., "Crystal structure of the cell-binding B oligomer of verotoxin-1 from E.coli", NATURE, MACMILLAN JOURNALS LTD., LONDON,UK, (19920220), vol. 355, pages 748 - 750, XP002096334 [DA] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1038/355748a0
 [PX]  - BRAY, M. R. ET AL, "Shiga-like toxin as a template for the development of anti-breast cancer agents.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 62-63. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERIC, XP002096335 [PX] 1-17 * Abstract no. 428; *
 [PX]  - BRAY, M. R. ET AL, "Expression of the Shiga-like toxin I receptor CD77 on human breast carcinomas, follicular lymphomas and multiple myelomas and absence of expression on CD34+ human hematopoietic cells: Implications for tumor cell purging.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 63. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERICAN, XP002096336 [PX] 18,21 * Abstract no. 429; *
 [PA]  - H. LING ET AL., "Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3", BIOCHEMISTRY, AM. CHEM. SOC.,WASHINGTON,DC,US, (19980217), vol. 37, pages 1777 - 1788, XP002096337 [PA] 1-26 * the whole document *

DOI:   http://dx.doi.org/10.1021/bi971806n
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.